S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Endo International plc stock logo
ENDP
Endo International
$0.00
$0.45
$0.28
$7.07
$165K1.1528.19 million shs1,026 shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$7.20
-2.8%
$11.18
$3.81
$17.70
$423.29M0.26277,536 shs219,365 shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$72.37
+0.5%
$69.31
$45.50
$84.89
$6.97B1.02938,140 shs2.19 million shs
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$29.40
+1.8%
$31.33
$21.99
$39.09
$1.61B0.99384,416 shs361,633 shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$15.13
+0.9%
$15.77
$4.60
$20.90
$662.39M0.74403,077 shs467,186 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Endo International plc stock logo
ENDP
Endo International
-85.00%+100.00%-25.00%+100.00%-99.12%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-8.86%-11.36%-25.30%-29.56%-30.29%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-6.12%+5.93%+10.01%+10.01%+15.83%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
-0.45%-9.78%-17.87%+4.34%-22.43%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-0.73%+2.53%+0.74%+59.91%+159.07%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Endo International plc stock logo
ENDP
Endo International
0.1984 of 5 stars
0.00.00.03.51.71.70.0
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
3.768 of 5 stars
3.30.00.04.61.94.20.6
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
4.0274 of 5 stars
3.52.00.04.52.42.50.6
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
3.9014 of 5 stars
3.51.00.04.12.10.81.9
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.3102 of 5 stars
1.21.00.00.01.04.20.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Endo International plc stock logo
ENDP
Endo International
N/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
2.50
Moderate Buy$17.44142.28% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.90
Moderate Buy$86.1719.06% Upside
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
3.00
Buy$41.0039.46% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.33
Hold$16.579.53% Upside

Current Analyst Ratings

Latest YMAB, IGMS, ENDP, ITCI, and SUPN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$12.00
4/17/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$80.00 ➝ $90.00
4/17/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$83.00 ➝ $103.00
4/17/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$82.00 ➝ $91.00
4/17/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$67.00 ➝ $77.00
4/16/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00
4/5/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00
4/3/2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$86.00
3/6/2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $22.00
3/4/2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$22.00 ➝ $26.00
3/4/2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$16.00 ➝ $26.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Endo International plc stock logo
ENDP
Endo International
$2.99B0.00$0.01 per share0.06($13.60) per share0.00
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$2.13M198.73N/AN/A$3.46 per share2.08
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$462.18M15.16N/AN/A$6.15 per share11.77
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$607.52M2.65$1.61 per share18.30$16.87 per share1.74
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$84.82M7.81N/AN/A$2.32 per share6.52

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Endo International plc stock logo
ENDP
Endo International
-$613.24M-$11.07N/A0.01N/A-93.31%-34.25%6.72%N/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$246.42M-$4.81N/AN/AN/A-11,568.83%-103.20%-53.53%5/10/2024 (Estimated)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$1.46N/A89.35N/A-30.08%-23.02%-19.39%5/2/2024 (Estimated)
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$1.32MN/A0.0020.00N/A0.22%0.14%0.09%5/14/2024 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$21.43M-$0.49N/AN/AN/A-25.26%-20.72%-16.28%5/13/2024 (Estimated)

Latest YMAB, IGMS, ENDP, ITCI, and SUPN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2023
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$1.06-$1.01+$0.05-$1.01$0.95 million$0.65 million
2/29/2024Q4 2023
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.19-$0.02+$0.17-$0.02$21.72 million$23.36 million
2/27/2024Q4 2023
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$0.41$0.02-$0.39$0.02$155.03 million$164.30 million    
2/22/2024Q4 2023
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$0.44-$0.30+$0.14-$0.30$135.97 million$132.10 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Endo International plc stock logo
ENDP
Endo International
N/AN/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Endo International plc stock logo
ENDP
Endo International
N/A
1.86
1.62
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
8.18
8.18
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
5.41
5.31
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A
1.70
1.43
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
5.52
5.27

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Endo International plc stock logo
ENDP
Endo International
3,103235.14 million232.32 millionNo Data
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
22458.79 million25.33 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
61096.81 million93.52 millionOptionable
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
65254.74 million49.94 millionOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
10043.78 million34.37 millionOptionable

YMAB, IGMS, ENDP, ITCI, and SUPN Headlines

SourceHeadline
New Strong Buy Stocks for April 19thNew Strong Buy Stocks for April 19th
zacks.com - April 19 at 7:50 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%
finance.yahoo.com - April 18 at 1:21 PM
New Strong Buy Stocks for April 17thNew Strong Buy Stocks for April 17th
zacks.com - April 17 at 8:30 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) & Dyne Therapeutics (NASDAQ:DYN) Critical ReviewY-mAbs Therapeutics (NASDAQ:YMAB) & Dyne Therapeutics (NASDAQ:DYN) Critical Review
americanbankingnews.com - April 14 at 1:32 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4%Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4%
americanbankingnews.com - April 13 at 6:36 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4%
marketbeat.com - April 11 at 11:58 AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Hold" from BrokeragesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Hold" from Brokerages
americanbankingnews.com - April 10 at 2:30 AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by AnalystsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Analysts
marketbeat.com - April 10 at 2:30 AM
Y-mAbs Therapeutics (NASDAQ:YMAB)  Shares Down 3.3% Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 3.3%
marketbeat.com - April 9 at 11:46 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%
marketbeat.com - April 3 at 3:27 PM
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19
marketbeat.com - April 2 at 11:19 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9%Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9%
marketbeat.com - April 1 at 2:01 PM
Denali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Denali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
marketbeat.com - April 1 at 6:12 AM
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a BetWall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
zacks.com - March 28 at 10:56 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%
marketbeat.com - March 26 at 12:38 PM
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
zacks.com - March 20 at 8:40 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4.3%Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4.3%
marketbeat.com - March 19 at 11:57 AM
Y-mAbs Therapeutics Finance Chief Bo Kruse ResignsY-mAbs Therapeutics Finance Chief Bo Kruse Resigns
marketwatch.com - March 15 at 8:31 AM
Y-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerY-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
finanznachrichten.de - March 14 at 2:58 PM
Y-mAbs Therapeutics CFO Bo Kruse To RetireY-mAbs Therapeutics CFO Bo Kruse To Retire
markets.businessinsider.com - March 14 at 9:57 AM
Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerY-mAbs Therapeutics Announces Resignation of Chief Financial Officer
globenewswire.com - March 14 at 9:05 AM
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
zacks.com - March 12 at 10:55 AM
BAMF, Corewell Health partner on clinical trial for advanced cancer treatmentBAMF, Corewell Health partner on clinical trial for advanced cancer treatment
crainsgrandrapids.com - March 11 at 3:17 PM
Cracking The Code: Understanding Analyst Reviews For Y-mAbs TherapeuticsCracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
markets.businessinsider.com - March 6 at 6:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Endo International logo

Endo International

NASDAQ:ENDP
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
IGM Biosciences logo

IGM Biosciences

NASDAQ:IGMS
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Intra-Cellular Therapies logo

Intra-Cellular Therapies

NASDAQ:ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Supernus Pharmaceuticals logo

Supernus Pharmaceuticals

NASDAQ:SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Y-mAbs Therapeutics logo

Y-mAbs Therapeutics

NASDAQ:YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.